The terminal complement complex, c5b–9, a marker of disease activity in patients with systemic lupus erythematosus
Concentrations of the terminal complement complex (TCC), C5b–9, were examined in 120 serum samples from 28 patients with systemic lupus erythematosus. Eleven patients with various manifestations of the disease were followed longitudinally for a 2‐year period during active and inactive phases of the...
Gespeichert in:
| Veröffentlicht in: | Arthritis and rheumatism 1988-02, Vol.31 (2), p.188-195 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 195 |
|---|---|
| container_issue | 2 |
| container_start_page | 188 |
| container_title | Arthritis and rheumatism |
| container_volume | 31 |
| creator | Gawryl, Maria S. Chudwin, David S. Langlois, Paul F. Lint, Thomas F. |
| description | Concentrations of the terminal complement complex (TCC), C5b–9, were examined in 120 serum samples from 28 patients with systemic lupus erythematosus. Eleven patients with various manifestations of the disease were followed longitudinally for a 2‐year period during active and inactive phases of the disease. In 9 of the 11 patients, elevations in TCC concentrations correlated with disease exacerbations. In many of these patients, C3 and C4 levels remained normal during the study and were less sensitive indicators of disease activity than were TCC concentrations. We believe that measurements of TCC are useful in monitoring patients with rheumatic diseases in which complement activation is a component. |
| doi_str_mv | 10.1002/art.1780310206 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_78150911</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>78150911</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4006-73efb31702a12af23546e1aa41a8449c48e6070066e6620478c9897c55135e7a3</originalsourceid><addsrcrecordid>eNqFkcluFDEQhi0ECkPgyg3JB5RTevDWXo5RxCZFQkLDuVXjVGsMvWG7E_qWd-ANeRIcTStwy6mq9H-1qH5CXnO25YyJdxDzlhvLJGeC6Sdkw2vhKsYlf0o2jDFVydrx5-RFSt9LKWQtT8iJlMpaITYk7w5IM8Y-DNBRP_ZThz0OeU1_nVNf7__c_XbnFGgP8QdGOrb0OiSEhBR8DjchLzQMdIIcSmeityEfaFpSxj542s3TnCjGJR-whzymOb0kz1roEr5a4yn59uH97vJTdfXl4-fLi6vKK8Z0ZSS2e8kNE8AFtOV0pZEDKA5WKeeVRc1MITVqLZgy1jvrjK9rLms0IE_J2XHuFMefM6bc9CF57DoYcJxTYyyvmeP8UZDff8sqWcDtEfRxTCli20wxlLcsDWfNvR9N8aP550dpeLNOnvc9Xj_gqwFFf7vqkDx0bYTBh_SAGS2tdqxg7ojdhg6XR5Y2F193_53wF_tWpAc</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>14882843</pqid></control><display><type>article</type><title>The terminal complement complex, c5b–9, a marker of disease activity in patients with systemic lupus erythematosus</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><source>Alma/SFX Local Collection</source><creator>Gawryl, Maria S. ; Chudwin, David S. ; Langlois, Paul F. ; Lint, Thomas F.</creator><creatorcontrib>Gawryl, Maria S. ; Chudwin, David S. ; Langlois, Paul F. ; Lint, Thomas F.</creatorcontrib><description>Concentrations of the terminal complement complex (TCC), C5b–9, were examined in 120 serum samples from 28 patients with systemic lupus erythematosus. Eleven patients with various manifestations of the disease were followed longitudinally for a 2‐year period during active and inactive phases of the disease. In 9 of the 11 patients, elevations in TCC concentrations correlated with disease exacerbations. In many of these patients, C3 and C4 levels remained normal during the study and were less sensitive indicators of disease activity than were TCC concentrations. We believe that measurements of TCC are useful in monitoring patients with rheumatic diseases in which complement activation is a component.</description><identifier>ISSN: 0004-3591</identifier><identifier>EISSN: 1529-0131</identifier><identifier>DOI: 10.1002/art.1780310206</identifier><identifier>PMID: 3348822</identifier><identifier>CODEN: ARHEAW</identifier><language>eng</language><publisher>New York: John Wiley & Sons, Inc</publisher><subject>Adult ; Biological and medical sciences ; Complement C3 - analysis ; Complement C4 - analysis ; Complement Membrane Attack Complex ; Complement System Proteins - analysis ; Female ; Humans ; Lupus Erythematosus, Systemic - drug therapy ; Lupus Erythematosus, Systemic - immunology ; Male ; Medical sciences ; Middle Aged ; Prednisone - administration & dosage ; Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis</subject><ispartof>Arthritis and rheumatism, 1988-02, Vol.31 (2), p.188-195</ispartof><rights>Copyright © 1988 American College of Rheumatology</rights><rights>1988 INIST-CNRS</rights><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4006-73efb31702a12af23546e1aa41a8449c48e6070066e6620478c9897c55135e7a3</citedby><cites>FETCH-LOGICAL-c4006-73efb31702a12af23546e1aa41a8449c48e6070066e6620478c9897c55135e7a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fart.1780310206$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fart.1780310206$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=7638690$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/3348822$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gawryl, Maria S.</creatorcontrib><creatorcontrib>Chudwin, David S.</creatorcontrib><creatorcontrib>Langlois, Paul F.</creatorcontrib><creatorcontrib>Lint, Thomas F.</creatorcontrib><title>The terminal complement complex, c5b–9, a marker of disease activity in patients with systemic lupus erythematosus</title><title>Arthritis and rheumatism</title><addtitle>Arthritis Rheum</addtitle><description>Concentrations of the terminal complement complex (TCC), C5b–9, were examined in 120 serum samples from 28 patients with systemic lupus erythematosus. Eleven patients with various manifestations of the disease were followed longitudinally for a 2‐year period during active and inactive phases of the disease. In 9 of the 11 patients, elevations in TCC concentrations correlated with disease exacerbations. In many of these patients, C3 and C4 levels remained normal during the study and were less sensitive indicators of disease activity than were TCC concentrations. We believe that measurements of TCC are useful in monitoring patients with rheumatic diseases in which complement activation is a component.</description><subject>Adult</subject><subject>Biological and medical sciences</subject><subject>Complement C3 - analysis</subject><subject>Complement C4 - analysis</subject><subject>Complement Membrane Attack Complex</subject><subject>Complement System Proteins - analysis</subject><subject>Female</subject><subject>Humans</subject><subject>Lupus Erythematosus, Systemic - drug therapy</subject><subject>Lupus Erythematosus, Systemic - immunology</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Prednisone - administration & dosage</subject><subject>Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis</subject><issn>0004-3591</issn><issn>1529-0131</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1988</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkcluFDEQhi0ECkPgyg3JB5RTevDWXo5RxCZFQkLDuVXjVGsMvWG7E_qWd-ANeRIcTStwy6mq9H-1qH5CXnO25YyJdxDzlhvLJGeC6Sdkw2vhKsYlf0o2jDFVydrx5-RFSt9LKWQtT8iJlMpaITYk7w5IM8Y-DNBRP_ZThz0OeU1_nVNf7__c_XbnFGgP8QdGOrb0OiSEhBR8DjchLzQMdIIcSmeityEfaFpSxj542s3TnCjGJR-whzymOb0kz1roEr5a4yn59uH97vJTdfXl4-fLi6vKK8Z0ZSS2e8kNE8AFtOV0pZEDKA5WKeeVRc1MITVqLZgy1jvrjK9rLms0IE_J2XHuFMefM6bc9CF57DoYcJxTYyyvmeP8UZDff8sqWcDtEfRxTCli20wxlLcsDWfNvR9N8aP550dpeLNOnvc9Xj_gqwFFf7vqkDx0bYTBh_SAGS2tdqxg7ojdhg6XR5Y2F193_53wF_tWpAc</recordid><startdate>198802</startdate><enddate>198802</enddate><creator>Gawryl, Maria S.</creator><creator>Chudwin, David S.</creator><creator>Langlois, Paul F.</creator><creator>Lint, Thomas F.</creator><general>John Wiley & Sons, Inc</general><general>Wiley</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>198802</creationdate><title>The terminal complement complex, c5b–9, a marker of disease activity in patients with systemic lupus erythematosus</title><author>Gawryl, Maria S. ; Chudwin, David S. ; Langlois, Paul F. ; Lint, Thomas F.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4006-73efb31702a12af23546e1aa41a8449c48e6070066e6620478c9897c55135e7a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1988</creationdate><topic>Adult</topic><topic>Biological and medical sciences</topic><topic>Complement C3 - analysis</topic><topic>Complement C4 - analysis</topic><topic>Complement Membrane Attack Complex</topic><topic>Complement System Proteins - analysis</topic><topic>Female</topic><topic>Humans</topic><topic>Lupus Erythematosus, Systemic - drug therapy</topic><topic>Lupus Erythematosus, Systemic - immunology</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Prednisone - administration & dosage</topic><topic>Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis</topic><toplevel>online_resources</toplevel><creatorcontrib>Gawryl, Maria S.</creatorcontrib><creatorcontrib>Chudwin, David S.</creatorcontrib><creatorcontrib>Langlois, Paul F.</creatorcontrib><creatorcontrib>Lint, Thomas F.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Arthritis and rheumatism</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gawryl, Maria S.</au><au>Chudwin, David S.</au><au>Langlois, Paul F.</au><au>Lint, Thomas F.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The terminal complement complex, c5b–9, a marker of disease activity in patients with systemic lupus erythematosus</atitle><jtitle>Arthritis and rheumatism</jtitle><addtitle>Arthritis Rheum</addtitle><date>1988-02</date><risdate>1988</risdate><volume>31</volume><issue>2</issue><spage>188</spage><epage>195</epage><pages>188-195</pages><issn>0004-3591</issn><eissn>1529-0131</eissn><coden>ARHEAW</coden><abstract>Concentrations of the terminal complement complex (TCC), C5b–9, were examined in 120 serum samples from 28 patients with systemic lupus erythematosus. Eleven patients with various manifestations of the disease were followed longitudinally for a 2‐year period during active and inactive phases of the disease. In 9 of the 11 patients, elevations in TCC concentrations correlated with disease exacerbations. In many of these patients, C3 and C4 levels remained normal during the study and were less sensitive indicators of disease activity than were TCC concentrations. We believe that measurements of TCC are useful in monitoring patients with rheumatic diseases in which complement activation is a component.</abstract><cop>New York</cop><pub>John Wiley & Sons, Inc</pub><pmid>3348822</pmid><doi>10.1002/art.1780310206</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0004-3591 |
| ispartof | Arthritis and rheumatism, 1988-02, Vol.31 (2), p.188-195 |
| issn | 0004-3591 1529-0131 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_78150911 |
| source | MEDLINE; Access via Wiley Online Library; Alma/SFX Local Collection |
| subjects | Adult Biological and medical sciences Complement C3 - analysis Complement C4 - analysis Complement Membrane Attack Complex Complement System Proteins - analysis Female Humans Lupus Erythematosus, Systemic - drug therapy Lupus Erythematosus, Systemic - immunology Male Medical sciences Middle Aged Prednisone - administration & dosage Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis |
| title | The terminal complement complex, c5b–9, a marker of disease activity in patients with systemic lupus erythematosus |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T20%3A52%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20terminal%20complement%20complex,%20c5b%E2%80%939,%20a%20marker%20of%20disease%20activity%20in%20patients%20with%20systemic%20lupus%20erythematosus&rft.jtitle=Arthritis%20and%20rheumatism&rft.au=Gawryl,%20Maria%20S.&rft.date=1988-02&rft.volume=31&rft.issue=2&rft.spage=188&rft.epage=195&rft.pages=188-195&rft.issn=0004-3591&rft.eissn=1529-0131&rft.coden=ARHEAW&rft_id=info:doi/10.1002/art.1780310206&rft_dat=%3Cproquest_cross%3E78150911%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=14882843&rft_id=info:pmid/3348822&rfr_iscdi=true |